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 Introduction 
 The Early Nutrition Academy (www.early-nutrition.
org) and the European Commission-funded EURRECA 
Network of Excellence (www.eurreca.org) jointly spon-
sored a scientific workshop on ‘Critical Micronutrients in 
Pregnancy, Lactation and Infancy’ held on June 14–16, 
2011, at Tutzing near Munich, Germany. The workshop 
was organized by the Dr. von Hauner Children’s Hospital, 
University of Munich Medical Centre, and ILSI Europe. 
Iron, folic acid, and vitamin D supplies in the perinatal 
period were chosen as the focus of the workshop because 
many open questions and controversial discussions exist 
with respect to these nutrients. The supply of vitamin D, 
folate, and iron is important for the health and well-being 
of pregnant women and their children. Among scientific 
bodies worldwide, the adequate supply of these micronu-
trients during the critical pre- and postnatal periods of life 
and the possible need for supplementation over and above 
typical dietary intakes are subjects of ongoing controversy 
and debate. The World Health Organisation (WHO) re-
ports that on a global basis a large proportion of pregnant 
women, infants, and children suffer from micronutrient 
deficiencies  [1] . However, there is a lack of harmonized and 
evidence-based recommendations for the supply of vita-
min D, folic acid, and iron during these periods of life.
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 Abstract 
 The Early Nutrition Academy and the European Commission-
funded EURRECA Network of Excellence jointly sponsored a 
scientific workshop on critical micronutrients in pregnancy, 
lactation, and infancy. Current knowledge and unresolved 
questions on the supply of vitamin D, folic acid, and iron for 
pregnant women, lactating women, and infants, and their 
health effects were discussed. The question was addressed 
of whether, and under which circumstances, supplementa-
tion with these micronutrients in addition to usual dietary 
intakes is advisable. The workshop participants concluded 
that public health strategies for improving supplementation 
with these micronutrients in pregnancy, lactation, and infan-
cy are required. Further research priorities should focus on 
adequately powered human intervention trials to obtain a 
stronger evidence base for the amounts of vitamin D, folic 
acid, and iron that have optimal effects on health. The con-
clusions of the workshop should help to inform the scien-
tific community as well as public health policy strategies. 
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 The aim of the workshop was to bring qualified ex-
perts and new investigators together to discuss current 
information, conclusions, and open questions and to 
identify future research priorities. Thirty-three partici-
pants from academia and from the industry, including 
new investigators, attended the workshop. Recent find-
ings on iron, folic acid, and vitamin D supply and effects 
during pregnancy, lactation, and infancy were presented. 
Ample time was allocated for discussions to address the 
question of whether supplementation with the micronu-
trients in question is necessary or advisable during dif-
ferent trimesters of pregnancy, during lactation, and/or 
during infancy. In further sessions, research priorities 
were discussed, and a summary of suggestions for future 
EU research funding has been forwarded to the Director-
ate-General Research of the European Commission for 
consideration. Here we try to summarize some of the 
main conclusions of the workshop. 
 Vitamin D 
 A large proportion of the global human population 
shows low concentrations of plasma 25(OH)D, which is 
considered a very good marker of vitamin D status. 
Many people do not achieve an adequate vitamin D sta-
tus because their sun exposure is not sufficient to pro-
vide enough endogenous vitamin D synthesis, while 
dietary vitamin D intake is low because there are few 
food sources.
 During pregnancy, vitamin D should support mater-
nal and fetal bone health and enable the maternal immu-
nological adaptation required to maintain a normal preg-
nancy. It is currently unclear whether or not vitamin D 
needs are increased during pregnancy. Observational 
studies indicate that an increased vitamin D status dur-
ing pregnancy may enhance bone mineralization in the 
offspring  [2] . Evidence from observational studies and 
also from intervention studies suggests that vitamin D 
supplementation might benefit immune function and the 
loss of tolerance occurring in preeclampsia  [3] . Observa-
tional studies show an association of increased vitamin D 
status with long-term protection against immunological 
diseases such as allergic diseases and type 1 diabetes but 
also with an increased risk of asthma and wheeze  [2] . A 
large proportion of pregnant women are vitamin D de-
pleted, as shown by low plasma 25(OH)D concentrations 
 [2, 4] . An individual assessment of vitamin D status dur-
ing pregnancy is rather expensive and therefore not fea-
sible on a population basis. 
 Supplementation of infants, in particular breast-fed 
infants who receive a lower dietary vitamin D supply than 
formula-fed infants, with about 400–500 IU vitamin D 
per day for the first year of life to prevent rickets is wide-
ly accepted and practiced. While infant formula is forti-
fied with vitamin D  [5] , complementary foods generally 
do not contain added vitamin D, except for some com-
mercial milk cereals. The provision and implementation 
of different recommendations for vitamin D supplemen-
tation for breast-fed infants and for formula-fed infants 
appears not to be practically feasible and would create 
further difficulties in practice due to the significant num-
ber of infants receiving both human milk and infant for-
mula in varying proportions. 
 Future research should be aimed at establishing better 
evidence of the effects of an increased supply of vitamin 
D during pregnancy on the health effects in mothers and 
offspring from controlled intervention trials, considering 
the influence of different geographic locations and life-
styles, ethnicity, and the effects of genetic and other inter-
individual variations. The currently rather limited evi-
dence of the effects of vitamin D supply in women and in 
infants and young children on health beyond bone  [6] , 
such as effects on muscle function and immune response, 
should be enhanced by adequately designed and powered 
controlled trials. 
 Folic Acid  
 Folate is essential for the synthesis of DNA and other 
critical cell components, especially during periods of rap-
id growth and cell division. Folate requirements are in-
creased during pregnancy due to increased cell multipli-
cation and metabolic turnover, placental and fetal devel-
opment, growth of the uterus, and maternal blood volume 
expansion. 
 The American Institute of Medicine considered the 
maintenance of a red blood cell (RBC) folate concentra-
tion  1 340 nmol/l as the primary indicator of an adequate 
folate status during pregnancy  [7] . A sufficient dietary 
intake would correspond to the amount of dietary folate 
equivalents needed to maintain this normal RBC folate 
status. A low folate status before and during the first tri-
mester of pregnancy is associated with serious congenital 
anomalies, in particular neural tube defects (NTDs) such 
as spina bifida and myelomeningocele, but also increased 
risks for other congenital abnormalities such as congeni-
tal heart defects and oral clefts have been proposed  [8] . 
Folic acid or folic acid-containing multivitamin supple-
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mentation from the preconception period through the 
first trimester of pregnancy effectively reduces NTD oc-
currence and may reduce cardiovascular and other mal-
formations  [9] . It has been suggested that multivitamins 
with folic acid may have a greater preventive benefit than 
the use of folic acid alone, but randomized controlled tri-
als with a direct comparison of both strategies have not 
been performed  [9] . Supplementation of 5-methylfolate 
has also been advocated for the prevention of congenital 
abnormalities, even though direct evidence from clinical 
studies is not available  [10] . Throughout pregnancy, an 
adequate folate supply reduces the risk of severe adverse 
outcomes such as maternal anemia, preeclampsia, pla-
cental abruption, low birth weight, and preterm birth. 
 The workshop participants concluded that a daily 
intake of 600   g of dietary folate equivalents usually 
achieves an adequate folate status during pregnancy. In-
creased consumption of folate-rich foods generally does 
not reach satisfactory intakes of folate necessary for the 
prevention of congenital anomalies. Therefore, supple-
mentation of folic acid from enriched foods and/or from 
supplements is recommended as the effective preventive 
measure. Women of childbearing age should receive in 
addition to a folate-rich diet at least 400   g folic acid per 
day from supplements, fortified foods, or both to prevent 
NTDs. These recommendations are based on a high evi-
dence level  [11] but, nonetheless, in many countries around 
the world implementation of effective measures to achieve 
a preventive folic acid intake is failing. This discrepancy 
constitutes a major public health challenge. For example, 
in the European Union only a small minority of pregnant 
women obtain a periconceptional folic acid supply at the 
recommended preventive dosage, and hence a large num-
ber of preventable malformations and severe suffering oc-
cur unnecessary. Increased information and motivation 
for women of childbearing age is needed, for example via 
campaigns through media, schools, and other settings. 
The concept of linking information on the preventive ef-
fects of folic acid to information on contraceptives was 
discussed with interest, and it was recommended to care-
fully evaluate the effects that might be achieved. The 
workshop participants recognized that promotion of in-
dividual folic acid supplementation has not achieved an 
appreciable reduction of NTD rates on a population level 
in all countries evaluated  [12] . In contrast, folic acid forti-
fication of staple foods such as flour and other cereal-
based foods, which is used in about 68 countries around 
the globe, has been demonstrated to effectively reduce 
NTDs  [13] . Initial concerns that folic acid fortification 
might increase the risk of neoplasm have not been sub-
stantiated  [14] , but there are reports showing that folic 
acid fortification of flour in the USA has resulted in a 
marked decline of deaths from coronary heart disease and 
particularly from stroke  [15] , apparently due to a small but 
consistent blood pressure-lowering effect. 
 Effects of folic acid supplementation in addition to a 
reasonable dietary intake during the second and third tri-
mesters of pregnancy on maternal and offspring health 
are not well documented. There is no conclusive evidence 
to support continued supplementation of pregnant wom-
en after the first semester of pregnancy, but there are also 
no indications of untoward effects. Further studies on 
this question are needed.
 Further research should investigate the mechanisms 
of risk reduction of NTDs by folates, which could inform 
more targeted preventive strategies and options for the 
evidence-based use of different metabolites. The effects 
of folic acid alone and in combination with multivitamin 
or multimicronutrient supplements should be better doc-
umented. The effects of an enhanced supply of folic acid 
or other folates in the second and third trimesters of preg-
nancy in infants and young children and also in the gen-
eral population should be explored in greater detail. The 
impact of folate supply before and during pregnancy on 
DNA methylation and possible associated biological ef-
fects should be investigated. The feasibility, effects, and 
health economic impact of different strategies towards 
improving folate status in European populations should 
be evaluated.
 Iron 
 Iron deficiency anemia (IDA) is the most frequent 
form of anemia in pregnancy, and the occurrence of IDA 
increases the risk of preterm delivery and low birth 
weight. Moreover, iron is essential for normal fetal devel-
opment, including brain development  [16] . Therefore, 
IDA in pregnant women must be prevented. The diet be-
fore and during pregnancy should be rich in bioavailable 
iron. In addition, supplementation of all pregnant women 
with a proven effective iron dose (e.g. 30–40 mg ferrous 
iron) has been suggested  [17] . However, there are con-
cerns about a lack of adequate benefit of such an approach 
while there are adverse effects particularly in iron-suffi-
cient women. Therefore, a more desirable option would 
be targeting supplementation to pregnant women at risk 
of IDA, e.g. with serum ferritin levels  ! 70   g/l.
 In infancy and early childhood, iron remains a critical 
substrate due to the rapid growth, development, and he-
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moglobin expansion during this period of life. The con-
siderable iron deposited at birth can become exhausted 
from the 5th to the 7th month of life onwards in healthy 
breast-fed infants born at full term because human breast 
milk has a low iron content. Hence, the risk of developing 
IDA in those infants is high from the end of the first half 
of the first year of life onwards. It is important to prevent 
IDA not only because of the direct consequences of ane-
mia but also because iron is critical for brain development 
and function. IDA deficiency in infancy has been associ-
ated with marked adverse effects on later neurodevelop-
ment in several case control studies  [18] . In affluent pop-
ulations such as those in European countries, healthy 
breast-fed infants generally do not need iron supple-
ments, and infant formulae do not need to provide high 
iron contents during the first months of life when iron 
stores are well filled and iron absorption is low  [19] . From 
the 5th to the 7th month of age onwards, a good supply of 
well bioavailable iron should be provided with comple-
mentary feeding in affluent populations  [20] , whereas 
complementary feeding should not be introduced before 
the 7th month of life in breast-fed infants in low-income 
countries with a high risk of infectious diarrhea. Iron 
supplements should not be given to iron-sufficient in-
fants before the 7th month of age because they may in-
duce adverse effects, e.g. on length-wise growth  [21] , and 
the effects of iron supplements on the early development 
of gut microbiota and associated effects remain to be elu-
cidated  [22] . However, iron supplements are regularly 
needed for preterm and low-birth-weight infants and for 
exclusively breast-fed term infants in low-income coun-
tries, and one needs to weigh the benefits against the re-
ported risks of iron supplementation of infants and chil-
dren in endemic malaria areas where increases in mor-
bidity and mortality have been reported  [22] . 
 With respect to priorities for further research on peri-
natal iron supply, data should be collected from observa-
tional studies on iron intake and iron status in pregnant 
women, infants, and toddlers in Europe, considering 
modifying factors such as dietary choices, iron absorp-
tion, and genetic variation. Further randomized clinical 
trials testing the effects of different doses of iron supple-
ments for pregnant women on maternal and infant out-
comes are needed. The effect of iron supply and status in 
breast-fed infants and in infants randomized to infant 
formula with different iron concentrations (e.g. in the 
range of 2–12 mg/l) in a European setting on outcomes 
such as motor and cognitive development, IDA, gut mi-
crobiota, infections, and immune response should be in-
vestigated, preferably with a long-term follow-up of sub-
jects up to school age. Moreover, the effects of a different 
iron supply during the second year of life, e.g. with iron-
fortified milk compared to regular cow’s milk, should be 
explored, considering outcomes similar to those men-
tioned above for infants. Future observational and in-
tervention studies should take advantage of modern 
methods to assess iron metabolism such as measures of 
hepticin and non-transferrin-bound iron to assess gut 
microbiota development, metabolomic response, geno-
type, and epigenetic effects.
 General Conclusions 
 Public health strategies for effectively improving the 
supply of vitamin D and folic acid, and in selected indi-
viduals also of iron, for pregnant and lactating women as 
well as their infants are urgently needed. Further research 
is needed with adequately powered, controlled human in-
tervention studies to obtain a stronger evidence base for 
the amounts of supplied vitamin D, folic acid, and iron 
that have optimal effects on short- and long-term health. 
In the case of vitamin D and folic acid, strategies for for-
tification of food products should be explored and evalu-
ated. 
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